Drugs
(asked on 16th December 2014) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what medicines the National Institute for Health and Care Excellence (NICE) (a) has evaluated and (b) intends to evaluate using the highly specialised technologies process; and what medicines his Department is planning to refer to NICE for assessment through that process.
The National Institute for Health and Care Excellence (NICE) has been asked to evaluate the following treatments under its highly specialised technologies (HST) programme:
Assessment title | Anticipated publication date |
Atypical haemolytic uraemic syndrome - eculizumab | January 2015 |
Gaucher disease (type 1) - eliglustat | August 2015 |
Mucopolysaccharidosis (type IVA) - elosulfase alfa | October 2015 |
Paediatric-onset hypophosphatasia - asfotase alfa | October 2015 |
NICE has not yet issued any final guidance through this programme.
A number of other medicines are being considered for referral to NICE’s HST programme through the established topic selection arrangements. Information on these is currently commercially confidential and cannot be released at this stage.